2nd Annual Antibody Summit: Discovery, Engineering and Therapeutics

May 2017



Hotel Novotel Barcelona City

Avenida Diagonal 201, 08018

About Summit

This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development. The Summit will shed light on current challenges, best practices and the inside view of the future of Antibodies. We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in the Antibodies.

Who Should Attend

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Managers, Clinical Development Experts and Scientists specialising in

  • Antibody & Biologics Discovery /Development
  • Protein Engineering
  • Medicinal Chemistry
  • Bioconjugates
  • Monoclonal antibodies (mAbs)
  • Tubulysins
  • PBD-dimers
  • Topoisomerase inhibitors
  • Small-molecule drug conjugates
  • Nanoparticles/Nanobodies
  • PKPD
  • Toxicology
  • Bioanalysis
  • Oncology
  • Antibody-based therapeutics
  • Immunotherapeutics
  • Manufacturing/CMC
  • Molecular Biology
  • Antibody-drug conjugates (ADCs)
  • Immunoconjugates
  • Maytansine
  • Duocarmycin
  • α-amanitin
  • Marine-based cytotoxins
  • Peptide-drug conjugates
  • Diabodies/Minibodies
  • ADME
  • Analytical & Formulation
  • Cancer
  • Hematology
  • Biotherapeutics
  • Chemotherapeutics
Key Practical Learning Points of the Summit

360° view of Antibody from key industry players to leverage your business and scientific practice adoption
Emerging discoveries, cutting-edge knowledge, tools, methods, and technologies to bring clinically safe and efficient Antibodies
Novel approaches and Antibody formats to accelerate Antibody therapeutics
Dr. Martin Steegmaier

Head of Discovery & Site Head Large Molecule Research Pharma Research & Early Development (pRED)

Roche Diagnostics GmbH, Germany

Dr. Brian Fennell

BioMedicine Design (BMD)

Pfizer, Ireland

Dr. Marina Feschenko

Principle Scientist

Biogen, US

Dr. Jürgen Schäfer

Mass Spectrometry Lab Head R&D / Pharmaceutics Development Platform / Analytical Sciences Frankfurt

Sanofi-Aventis Deutschland GmbH, Germany

Dr. Kay-Gunnar Stubenrauch

Sr. Principal Scientist Pharmaceutical Sciences Division of pRED (Pharma Research & Early Development)

Roche Innovation Center Munich, Germany

Dr. Anke Steinmetz

Senior Researcher

Sanofi, France

Dr. Ulrich Rümenapp

Head of Launch Preparation & Coordination

Bayer Pharma AG, Germany

Dr. Stefan R. Schmidt

Senior Vice President Process Science & Production

Rentschler Biotechnologie GmbH, Germany

Dr. Julia Neugebauer

Associate Director / Leader Discovery Programs

MorphoSys AG, Germany

Charlotte Hagman

Chemical Biology, Biochemistry, Analytical Chemistry

Novartis AG

Ronan O'Dwyer

Senior Scientist

Immunocore Ltd

Frank S. Walsh

CEO & Professor

Ossianix Inc & Kings College London

Salvador Ventura

Chair Prof. of Biochemistry & Molecular Biology

Universitat Autònoma de Barcelona Spain

Eugene Zhukovsky

Chief Scientific Officer

BIOMUNEX Pharmaceuticals

Manuela Duerr

Project Manager Immuno-Oncology

Pieris Pharmaceuticals GmbH

Lucia D'Amico

Department of Biomedicine

University Hospital Basel

Lauren Ely

Principal Scientist

Centers for Therapeutic Innovation, Pfizer, Inc

Mark Chiu

Biologics Engineering and Function

Janssen Research and Development

Matthew Beard

Senior Principal Scientist

Ipsen Bioinnovation Ltd

Dr. Malathi Raman

European Product Manager

Takara Bio Europe, France



Sponsors and Partners







Media partner

Media partner

Media partner

Media partner

Media partner

Media partner